Previous 10 | Next 10 |
CAMBRIDGE, Mass. , May 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from the ongoing ARROW clinical trial of pralsetinib in pat...
CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming inves...
CAMBRIDGE, Mass. , May 26, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webc...
Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...
CytomX Stock Slumps on Disappointing Probody Data CytomX Therapeutics ( CTMX ) slumped as the company provided updates about its two lead drug candidates CX-072 and CX-2009. The company had also recently reported its financial results for the first quarter of 2020 and offered business upda...
Nasdaq has suspended trading in Deciphera Pharmaceuticals ( DCPH +6.6% ) pending the release of news. More news on: Deciphera Pharmaceuticals, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, Read more ...
Blueprint Medicines (NASDAQ: BPMC ) reports that it has received a Complete Response Letter (CRL) from the FDA regarding its marketing application for avapritinib in fourth-line gastrointestinal tumor (GIST). More news on: Blueprint Medicines Corporation, Bayer Aktiengesellschaft, Deciph...
CAMBRIDGE, Mass. , May 15, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has issued a co...
CAMBRIDGE, Mass. , May 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated clinical data for pralsetinib in RET-al...
Blueprint Medicines ( BPMC +10.7% ) is poised for its best one-day gain in a month on the heels of a note from SVB Leerink on RET inhibitor pralsetinib (BLU-667). More news on: Blueprint Medicines Corporation, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, Read mo...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-05-13 18:15:03 ET Stephens analyst issues OVERWEIGHT recommendation for BPMC on May 13, 2024 04:31PM ET. BPMC was trading at $108.05 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 3 - Hold ...
2024-05-09 15:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 30.3% to $0.2932 on volume of 173,918,707 shares Emergent Biosolutions Inc. (EBS) rose 71.0% to $3.3 on volume of 150,987,238 shares PROSHARES TRUST (SQQQ) fell 3.6% to $11.78 on volume of 136,332,744 sh...